Indication: Advanced Solid Tumors
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
Sub-indication: Miscellaneous Malignancies
Study Type: Drug Study
Principal Investigator: John Hamm, M.D.Norton Cancer Institute
Sponsor: Sponsor: Seattle Genetics, Inc